Document:

EX-10.20

 Exhibit 10.20 
 INTELLECTUAL PROPERTY SECURITY AGREEMENT 
 This Intellectual Property
Security Agreement is entered into as of the Effective Date by and between OXFORD FINANCE LLC, as collateral agent for the Lenders (the “Lenders”) described in the Loan Agreement (in such capacity, the “Collateral Agent”) and
PROTOX THERAPEUTICS INC. (“Grantor”). 
 RECITALS 

A. Lenders have agreed to make certain advances of money and to extend certain financial accommodation to Grantor (the “Loans”)
in the amounts and manner set forth in that certain Loan and Security Agreement by and among Collateral Agent, the Lenders, Protox Therapeutics Corp. and Grantor dated the Effective Date (as the same may be amended, modified or supplemented from
time to time, the “Loan Agreement”; capitalized terms used herein are used as defined in the Loan Agreement). The Lenders are willing to make the Loans to Grantor, but only upon the condition, among others, that Grantor shall grant to
Collateral Agent, for the benefit of the Lenders, a security interest in certain Copyrights, Trademarks, Patents, and Mask Works to secure the obligations of Grantor under the Loan Agreement. 

B. Pursuant to the terms of the Loan Agreement, Grantor has granted to Collateral Agent, for the benefit of the Lenders, a security
interest in all of Grantor’s right, title and interest, whether presently existing or hereafter acquired, in, to and under all of the Collateral. 
 NOW, THEREFORE, for good and valuable consideration, receipt of which is hereby acknowledged, and intending to be legally bound, as collateral security for the prompt and complete payment when due of its
obligations under the Loan Agreement, Grantor hereby represents, warrants, covenants and agrees as follows: 
 AGREEMENT

 To secure its obligations under the Loan Agreement, Grantor grants and pledges to Collateral Agent, for the benefit of
the Lenders, a continuing security interest in all of Grantor’s right, title and interest in, to and under its Intellectual Property (including without limitation those Copyrights, Patents and Trademarks listed on Exhibits A, B and C hereto),
and including without limitation all proceeds thereof (such as, by way of example but not by way of limitation, license royalties and proceeds of infringement suits), the right to sue for past, present and future infringements, all rights
corresponding thereto throughout the world and all re-issues, divisions continuations, renewals, extensions and continuations-in-part thereof. 
 This security interest is granted in conjunction with the security interest granted to Collateral Agent, for the benefit of the Lenders, under the Loan Agreement. The rights and remedies of Collateral
Agent with respect to the security interest granted hereby are in addition to those set forth in the Loan Agreement and the other Loan Documents, and those which are now or hereafter available to Collateral Agent, for the benefit of the Lenders, as
a matter of law or equity. Each right, power and remedy of Collateral Agent provided for herein or in the Loan Agreement or any of the Loan Documents, or now or hereafter existing at law or in equity shall be cumulative and concurrent and shall be
in addition to every right, power or remedy provided for herein and the exercise by Collateral Agent of any one or more of the rights, powers or remedies provided for in this Intellectual Property Security Agreement, the Loan Agreement or any of the
other Loan Documents, or now or hereafter existing at law or in equity, shall not preclude the simultaneous or later exercise by any person, including Lender, of any or all other rights, powers or remedies. 

New York law governs this Intellectual Property Security Agreement without regard to principles of conflicts of law. This Intellectual
Property Security Agreement may be executed in any number of counterparts and by different parties on separate counterparts, each of which, when executed and delivered, is an original, and all taken together, constitute one agreement. 

[Balance of Page Intentionally Left Blank] 

 IN WITNESS WHEREOF, the parties have caused this Intellectual Property Security Agreement to
be duly executed by its officers thereunto duly authorized as of the first date written above. 
  

							
	GRANTOR:	 		 		 	
			
	Address of Grantor:	 		 	PROTOX THERAPEUTICS, INC.
				
	1500 – 885 West Georgia Street,	 		 	By:	 	 /s/ A. Hulme

	Vancouver, British Columbia, Canada, V6C 3E8	 		 		 	
	Attn: Chief Financial Officer	 		 	Title:	 	 Chief Operating Officer

			
		 		 	COLLATERAL AGENT:
			
	Address of Lender:	 		 	OXFORD FINANCE LLC
				
	133 North Fairfax Street	 		 	By:	 	 /s/ TAZ

	Alexandria, Virginia 22314	 		 		 	
	Attn: General Counsel	 		 	Title:	 	 COO

 [Signature Page to Intellectual Property Security Agreement] 

 EXHIBIT A 
 Copyrights 
  

					
	 Description
	  	 Registration Number
	  	 Registration Date

			
	 None.
	  		  	

 EXHIBIT B 
 Patents 
  

							
	 Description
	  	 Patent/App. No.
	  	 File Date
	  	Country
				
	Proaerolysin containing protease activation sequences and methods of use for treatment of prostate cancer	  	2002331720	  	8/23/02	  	Australia
				
	Proaerolysin containing protease activation sequences and methods of use for treatment of prostate cancer	  	2,457,903	  	8/23/02	  	Canada
				
	Proaerolysin containing protease activation sequences and methods of use for treatment of prostate cancer	  	2816622.1	  	8/23/02	  	China
				
	Proaerolysin containing protease activation sequences and methods of use for treatment of prostate cancer	  	2768702.9	  	8/23/02	  	EPC
				
	Proaerolysin containing protease activation sequences and methods of use for treatment of prostate cancer	  	TBD (divisional)	  	8/23/02	  	EPC
				
	Proaerolysin containing protease activation sequences and methods of use for treatment of prostate cancer	  	2003-523270	  	8/23/02	  	Japan
				
	Proaerolysin containing protease activation sequences and methods of use for treatment of prostate cancer	  	10/487,115	  	2/18/04	  	U.S.
				
	Proaerolysin containing protease activation sequences and methods of use for treatment of prostate cancer	  	11/856,543	  	9/17/07	  	U.S.
				
	Proaerolysin containing protease activation sequences and methods of use for treatment of prostate cancer	  	12/788,913	  	5/27/10	  	U.S.
				
	Proaerolysin containing protease activation sequences and methods of use for treatment of prostate cancer	  	2004/02319	  	8/23/02	  	South Africa
				
	Proaerolysin containing protease activation sequences and methods of use for treatment of prostate cancer	  	00379/KOLNP/04	  	8/23/02	  	India
				
	Proaerolysin containing protease activation sequences and methods of use for treatment of prostate cancer	  	2389/KOLNP/2007	  	3/22/04	  	India
				
	Modified pore-forming protein toxins and use thereof	  	12/094,597	  	11/21/06	  	U.S.
				
	Modified pore-forming protein toxins and use thereof	  	2630559	  	11/21/06	  	Canada
				
	Modified pore-forming protein toxins and use thereof	  	6804758.8	  	11/21/06	  	EPC
				
	Modified pore-forming protein toxins and use thereof	  	11166965.1	  	5/20/11	  	EPC
				
	Method of treating or preventing benign prostatic hyperplasia using modified pore-forming proteins	  	2006257664	  	6/14/06	  	Australia
				
	Method of treating or preventing benign prostatic hyperplasia using modified pore-forming proteins	  	2,611,839	  	6/14/06	  	Canada

							
	Method of treating or preventing benign prostatic hyperplasia using modified pore-forming proteins	 	200680028473.6	 	6/14/06	 	China
				
	Method of treating or preventing benign prostatic hyperplasia using modified pore-forming proteins	 	6761050.1	 	6/14/06	 	EPC
				
	Method of treating or preventing benign prostatic hyperplasia using modified pore-forming proteins	 	188143	 	6/14/06	 	Israel
				
	Method of treating or preventing benign prostatic hyperplasia using modified pore-forming proteins	 	2008-516088	 	6/14/06	 	Japan
				
	Method of treating or preventing benign prostatic hyperplasia using modified pore-forming proteins	 	564954	 	6/14/06	 	New Zealand
				
	Method of treating or preventing benign prostatic hyperplasia using modified pore-forming proteins	 	200718733-9	 	6/14/06	 	Singapore
				
	Method of treating or preventing benign prostatic hyperplasia using modified pore-forming proteins	 	11/921,964	 	12/10/07	 	U.S.
				
	Method of treating or preventing benign prostatic hyperplasia using modified pore-forming proteins	 	10-2008-7001038	 	6/14/06	 	Korea
				
	Method of treating or preventing benign prostatic hyperplasia using modified pore-forming proteins	 	2007/10813	 	6/14/06	 	South Africa
				
	Method for treating prostatitis utilizing modified pore-forming protein proaerolysin	 	PCT/CA2009/001837	 	12/15/09	 	PCT
				
	Circularly permuted ligands and circularly permuted chimeric molecules	 	08/225,224	 	6/03/97	 	U.S.
				
	Circularly permuted ligands and circularly permuted chimeric molecules	 	1995022857	 	11/5/98	 	Australia
				
	Circularly permuted ligands and circularly permuted chimeric molecules	 	2,187,283	 	9/23/08	 	Canada
				
	Circularly permuted ligands and circularly permuted chimeric molecules	 	95916319.7	 	1/29/03	 	EPC
				
	Circularly permuted ligands and circularly permuted chimeric molecules	 	08/722,258	 	12/10/07	 	U.S.
				
	Convection enhanced drug delivery	 	616,785	 	2/24/98	 	U.S.
				
	Method for convection enhanced delivery of therapeutic agents	 	2003299140	 	9/24/03	 	Australia
				
	Method for convection enhanced delivery of therapeutic agents	 	2,499,573	 	9/24/03	 	Canada
				
	Method for convection enhanced delivery of therapeutic agents	 	3756863.1	 	9/24/03	 	EPC

							
	Method for convection enhanced delivery of therapeutic agents	 	10/528,310	 	9/24/03	 	U.S.
				
	Treating cancer stem cells using targeted cargo proteins	 	PCT/CA2009/001323	 	9/21/09	 	PCT
				
	Treating cancer stem cells using targeted cargo proteins	 	13/119,426	 	3/16/11	 	U.S.
				
	Targeted cargo protein combination therapy	 	12/579,281	 	10/14/09	 	U.S.
				
	Use of human serum albumin to decrease antigenicity of therapeutic proteins	 	61/406,052	 	10/22/10	 	U.S. Provisional
				
	Methods and compositions for inhibiting cell death or enhancing cell proliferation	 	2,622,504	 	9/8/06	 	Canada
				
	Methods and compositions for inhibiting cell death or enhancing cell proliferation	 	6851440.5	 	9/8/06	 	EPC
				
	Methods and compositions for inhibiting cell death or enhancing cell proliferation	 	2008-536580	 	9/8/06	 	Japan
				
	Methods and compositions for inhibiting cell death or enhancing cell proliferation	 	11/91,692	 	9/8/06	 	U.S.
				
	Receptor-mediated uptake of an extracellular BCL-XL fusion protein inhibits apoptosis	 		 	5/15/04	 	U.S.
				
	Receptor-mediated uptake of an extracellular BCL-XL fusion protein inhibits apoptosis	 	12/147,924	 	6/27/08	 	U.S. Divisional

 EXHIBIT C 
 Trademarks 
  

					
	 Description
	  	 Serial/Registration No.
	  	 File Date

			
	None.EX-10.21

 Exhibit 10.21 
 INTELLECTUAL PROPERTY SECURITY AGREEMENT 
 This Intellectual Property
Security Agreement is entered into as of the Effective Date by and between OXFORD FINANCE LLC, as collateral agent for the Lenders (the “Lenders”) described in the Loan Agreement (in such capacity, the “Collateral Agent”) and
PROTOX THERAPEUTICS CORP. (“Grantor”). 
 RECITALS 

A. Lenders have agreed to make certain advances of money and to extend certain financial accommodation to Grantor (the “Loans”)
in the amounts and manner set forth in that certain Loan and Security Agreement by and among Collateral Agent, the Lenders, Protox Therapeutics Inc. and Grantor dated the Effective Date (as the same may be amended, modified or supplemented from time
to time, the “Loan Agreement”; capitalized terms used herein are used as defined in the Loan Agreement). The Lenders are willing to make the Loans to Grantor, but only upon the condition, among others, that Grantor shall grant to
Collateral Agent, for the benefit of the Lenders, a security interest in certain Copyrights, Trademarks, Patents, and Mask Works to secure the obligations of Grantor under the Loan Agreement. 

B. Pursuant to the terms of the Loan Agreement, Grantor has granted to Collateral Agent, for the benefit of the Lenders, a continuing
security interest in all of Grantor’s right, title and interest, whether presently existing or hereafter acquired, in, to and under all of the Collateral. 
 NOW, THEREFORE, for good and valuable consideration, receipt of which is hereby acknowledged, and intending to be legally bound, as collateral security for the prompt and complete payment when due of its
obligations under the Loan Agreement, Grantor hereby represents, warrants, covenants and agrees as follows: 
 AGREEMENT

 To secure its obligations under the Loan Agreement, Grantor grants and pledges to Collateral Agent, for the benefit of
the Lenders, a security interest in all of Grantor’s right, title and interest in, to and under its Intellectual Property (including without limitation those Copyrights, Patents and Trademarks listed on Exhibits A, B and C hereto), and
including without limitation all proceeds thereof (such as, by way of example but not by way of limitation, license royalties and proceeds of infringement suits), the right to sue for past, present and future infringements, all rights corresponding
thereto throughout the world and all re-issues, divisions, continuations, renewals, extensions and continuations-in-part thereof. 
 This security interest is granted in conjunction with the security interest granted to Collateral Agent, for the benefit of the Lenders, under the Loan Agreement. The rights and remedies of Collateral
Agent with respect to the security interest granted hereby are in addition to those set forth in the Loan Agreement and the other Loan Documents, and those which are now or hereafter available to Collateral Agent, for the benefit of the Lenders, as
a matter of law or equity. Each right, power and remedy of Collateral Agent provided for herein or in the Loan Agreement or any of the Loan Documents, or now or hereafter existing at law or in equity shall be cumulative and concurrent and shall be
in addition to every right, power or remedy provided for herein and the exercise by Collateral Agent of any one or more of the rights, powers or remedies provided for in this Intellectual Property Security Agreement, the Loan Agreement or any
of the other Loan Documents, or now or hereafter existing at law or in equity, shall not preclude the simultaneous or later exercise by any person, including Lender, of any or all other rights, powers or remedies. 

New York law governs this Intellectual Property Security Agreement without regard to principles of conflicts of law. This
Intellectual Property Security Agreement may be executed in any number of counterparts and by different parties on separate counterparts, each of which, when executed and delivered, is an original, and all taken together, constitute one
agreement. 
 [Balance of Page Intentionally Left Blank] 

 IN WITNESS WHEREOF, the parties have caused this Intellectual Property Security Agreement to
be duly executed by its officers thereunto duly authorized as of the first date written above. 
 GRANTOR:

  

									
	Address of Grantor:	 		 	 PROTOX THERAPEUTICS CORP.

 

				
	 c/o 1500 – 885 West Georgia Street
	 		 	By:	 	 /s/ A. Hulme

	Vancouver, British Columbia, Canada, V6C 3E8	 		 		 	
	Attn: Chief Financial Officer	 		 	Title:	 	 Chief Operating Officer

  

									
	  
 Address of Lender:
	 		 	 COLLATERAL AGENT:
  

OXFORD FINANCE LLC

				
	 133 North Fairfax Street
	 		 	By:	 	 /s/ TAZ

	Alexandria, Virginia 22314	 		 		 	
	Attn: General Counsel	 		 	Title:	 	 COO

 [Signature Page to Intellectual Property Security Agreement] 

 EXHIBIT A 
 Copyrights 
  

					
	 Description
	  	Registration Number	  	Registration Date
	 None.
	  		  	

 EXHIBIT B 
 Patents 
  

					
	 Description
	  	Patent/App. No.	  	File Date
	 None.
	  		  	

 EXHIBIT C 
 Trademarks 
  

					
	 Description
	  	Serial/Registration No.	  	File Date
	 None.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00212-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00212-of-00352.parquet"}]]